{"product_id":"lung-marketing-mix","title":"(LUNG) Pulmonx Corporation Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Pulmonx Corporation 4P's Marketing Mix Analysis explains the company’s product offering, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the content on this page is a genuine preview of the report so you can evaluate style and substance before buying—purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZephyr Endobronchial Valve\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZephyr Endobronchial Valve is Pulmonx Corporation’s core therapy for adults with severe emphysema and bronchoscopic hyperinflation, and it is used by physicians to lower air trapped in targeted lung lobes. It is a minimally invasive, one-way endobronchial device and remains the center of Pulmonx’s treatment portfolio. In 2025, Pulmonx still relied on Zephyr as its main revenue driver, with the company’s full-year sales base concentrated almost entirely in this product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChartis Pulmonary Assessment System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChartis Pulmonary Assessment System is Pulmonx Corporation’s companion diagnostic for Zephyr Valve workups, used to test for collateral ventilation before treatment. It combines 1 specialized balloon catheter, a console, and flow and pressure sensors to measure airflow and pressure in real time. That helps clinicians spot suitable candidates and avoid treating patients unlikely to benefit. In practice, it supports the same pre-screening step that underpins Zephyr Valve use in severe emphysema.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStratX Lung Analysis Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStratX Lung Analysis Platform is a cloud-based CT tool that gives clinicians 3 key readouts for emphysema planning: destruction score, fissure completeness, and lobar volume. It helps identify target lobes for Zephyr Valve placement, which matters because Pulmonx Corporation generated $77.5 million in Q1 2025 revenue. Faster, data-driven targeting can support better patient selection and workflow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSevere Emphysema Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePulmonx focuses on severe emphysema, a high-need COPD segment, with a procedure-led model built around patient selection, CT-based anatomy review, and bronchoscopic treatment using the Zephyr Valve and Chartis system. That narrow focus makes the portfolio specialist, not broad, and ties demand to hospital procedure volumes rather than general respiratory device sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSevere emphysema is Pulmonx's core use case\u003c\/li\u003e\n\u003cli\u003eScreening and anatomy drive treatment choice\u003c\/li\u003e\n\u003cli\u003eBronchoscopic therapy supports recurring procedure revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMinimally Invasive Bronchoscopic Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePulmonx Corporation’s core product is a minimally invasive bronchoscopic treatment for severe emphysema, built around device-based care instead of open surgery. The central value is simple: a doctor reaches the lungs with bronchoscopy and places valves to reduce hyperinflation, which can help patients breathe better without major surgery.\u003c\/p\u003e\n\u003cp\u003eThis is Pulmonx Corporation’s main product edge: less invasive delivery, shorter recovery, and a clear fit for patients who are poor surgical candidates. It is the company’s flagship category and the key driver behind its bronchoscopy-first portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBronchoscopy, not open surgery\u003c\/li\u003e\n\u003cli\u003eDevice-based care for emphysema\u003c\/li\u003e\n\u003cli\u003eCore Pulmonx value proposition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePulmonx’s Zephyr Valve Drives Revenue as Screening Tools Support Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePulmonx Corporation’s product mix is centered on Zephyr Endobronchial Valve, a minimally invasive bronchoscopy therapy for severe emphysema. Chartis and StratX support patient screening and lobe targeting, so the product stack is built around selection, planning, and treatment. In Q1 2025, Pulmonx reported $77.5 million in revenue, with Zephyr still the main sales driver.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZephyr Valve\u003c\/td\u003e\n\u003ctd\u003eCore therapy\u003c\/td\u003e\n\u003ctd\u003eMain revenue driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChartis\u003c\/td\u003e\n\u003ctd\u003eDiagnostic support\u003c\/td\u003e\n\u003ctd\u003ePre-treatment screening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStratX\u003c\/td\u003e\n\u003ctd\u003eCT planning tool\u003c\/td\u003e\n\u003ctd\u003eHelps target lobes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific analysis of Pulmonx’s Product, Price, Place, and Promotion strategy, grounded in real-world market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTurns Pulmonx Corporation’s 4Ps into a quick, pain-point-relieving snapshot for fast strategy reviews and team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, clinical data, and government datasets to let investors and buyers verify Pulmonx assumptions quickly and traceably.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRedwood City, California\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePulmonx Corporation keeps its headquarters in Redwood City, California, and that site anchors its global operations and commercial team. The base sits in Silicon Valley, a key medtech hub, and gives the Company direct access to talent, partners, and capital. In 2025, Pulmonx remained centered there as the main control point for management and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe United States is Pulmonx Corporation’s core market for emphysema patients, physician education, and device adoption. The company’s Zephyr Valves address a U.S. COPD burden of about 16 million diagnosed adults, which supports steady referral and treatment demand. In practice, the U.S. remains the main sales engine for Pulmonx’s commercial rollout and clinical outreach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurope\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurope is a core international market for Pulmonx Corporation, where Zephyr, Chartis, and StratX are part of its commercial footprint. The region matters because specialist pulmonary interventions are concentrated in advanced hospital centers, and Europe’s aging population supports demand for minimally invasive COPD care. Pulmonx’s latest public filings show Europe remains central to its global expansion, with the company continuing to invest in clinical adoption and physician training.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMiddle East and Africa\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePulmonx serves customers in the Middle East and Africa, extending its reach beyond North America and Western Europe. That matters for Place because COPD caused 3.23 million deaths worldwide in 2019, and broader coverage helps more patients reach emphysema treatment technologies like Zephyr valves.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands access beyond core Western markets.\u003c\/li\u003e\n\u003cli\u003eSupports regional COPD care delivery.\u003c\/li\u003e\n\u003cli\u003eFits a global, hospital-based sales model.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAsia-Pacific\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAsia-Pacific is a key international market for Pulmonx Corporation, giving the company a second large commercial base beyond the U.S. The region supports Zephyr valve adoption in countries like Japan and Australia, where chronic obstructive pulmonary disease remains a major respiratory burden. This helps Pulmonx spread commercial risk and widen its lung volume reduction reach.\u003c\/p\u003e\n\u003cp\u003eFor 2025, Pulmonx still framed non-U.S. sales as a core growth driver, and Asia-Pacific sits inside that push. The region matters because respiratory device uptake can scale fast once reimbursement, training, and referral paths are in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMajor non-U.S. growth market\u003c\/li\u003e\n\u003cli\u003eSupports Zephyr valve expansion\u003c\/li\u003e\n\u003cli\u003eDiversifies revenue beyond the U.S.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePulmonx’s Global Reach Starts in Redwood City\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePulmonx Corporation’s Place strategy centers on Redwood City, California, which anchors management, sales, and global execution in 2025. The U.S. stays the core market, supported by about 16 million diagnosed adults with COPD. Europe, Asia-Pacific, and the Middle East and Africa extend access to Zephyr valve care through hospital-based specialists.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRegion\u003c\/th\u003e\n\u003cth\u003ePlace role\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRedwood City\u003c\/td\u003e\n\u003ctd\u003eHQ and control point\u003c\/td\u003e\n\u003ctd\u003eSilicon Valley base in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003eMain sales engine\u003c\/td\u003e\n\u003ctd\u003eAbout 16 million diagnosed COPD adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope\u003c\/td\u003e\n\u003ctd\u003eCore international market\u003c\/td\u003e\n\u003ctd\u003eSupports Zephyr, Chartis, StratX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia-Pacific\u003c\/td\u003e\n\u003ctd\u003eGrowth market\u003c\/td\u003e\n\u003ctd\u003eDiversifies revenue beyond the U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePulmonx Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Pulmonx Corporation 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eIt covers Product, Price, Place and Promotion in a ready-made, editable format tailored for immediate use in strategy or investment work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePulmonx promotion leans on clinical evidence, because Zephyr valve use in emphysema depends on physician trust and tight patient selection. The company’s core studies, including LIBERATE and EMPROVE, showed lung-function and quality-of-life gains that helped win adoption. That evidence-first message matters in a market where outcomes, not ads, drive use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePulmonx Corporation must train pulmonologists, bronchoscopists, and treatment centers to select the right patients and match the right lobe for Zephyr Valve use. This matters because endobronchial valve therapy works only when selection is precise, and FDA clearance covers severe emphysema with little to no collateral ventilation. Strong physician education supports wider adoption and more consistent clinical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conference Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePulmonx uses respiratory and pulmonary conferences to show Zephyr valves and Chartis data, build trust, and reach treatment centers. These events put the Company in front of key opinion leaders and clinicians who shape referral and adoption decisions. Conference presence is a core promotion tool for specialty medtech, because trial results and real-world evidence matter most in severe COPD care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDirect Sales Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePulmonx Corporation sells into hospitals and specialist centers, so direct clinical sales support is a core part of promotion. In fiscal 2025, the Company reported revenue growth driven by broader adoption of its procedure-based lung volume reduction tools, which makes field education and workflow help even more important.\u003c\/p\u003e\n\u003cp\u003eSales teams help physicians learn the procedure, speed account setup, and support ongoing use, which matters in a hospital market where buying decisions are clinical and multi-step.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical education drives adoption.\u003c\/li\u003e\n\u003cli\u003eWorkflow support helps usage stick.\u003c\/li\u003e\n\u003cli\u003eAccount development matters in hospitals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor Communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePulmonx Corporation uses earnings releases, SEC filings, and shareholder updates to explain commercial progress, regulatory news, and market expansion. In 2025, this keeps investors focused on core metrics like revenue growth, gross margin, and adoption of the Zephyr valve.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic updates shape analyst and investor views.\u003c\/li\u003e\n\u003cli\u003eMessages track sales, regulation, and expansion.\u003c\/li\u003e\n\u003cli\u003eClear filings support market trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePulmonx Drives Zephyr Adoption with Data, Training, and KOL Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePulmonx promotion is evidence-led: LIBERATE and EMPROVE support Zephyr adoption, while field teams teach patient selection and procedure setup. The Company also uses pulmonary conferences and SEC updates to reach clinicians and investors. In fiscal 2025, broader Zephyr adoption made clinical education and workflow support even more important.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical data\u003c\/td\u003e\n\u003ctd\u003eBuild trust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales training\u003c\/td\u003e\n\u003ctd\u003eSpeed adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eReach KOLs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo Public Consumer Price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePulmonx Corporation has no public consumer price because it does not sell a retail product. Its Zephyr Valve and Chartis system are priced through hospital and institutional purchasing channels, so pricing is negotiated case by case. Public list prices are not disclosed in the source information.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Procurement Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePulmonx Corporation’s hospital procurement pricing is usually negotiated with hospitals, health systems, and distributors, not posted online, which is standard for specialist devices used in bronchoscopy procedures. Institutional buying makes the real price less visible than consumer markets, and FY2025 hospital contracts often hinge on volume, training, and reimbursement fit. That means pricing power depends more on clinical adoption than on list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcedure Based Economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZephyr Valve pricing is really procedure pricing: it only matters inside the severe emphysema treatment episode, where physician adoption and payer reimbursement shape demand. Pulmonx reported $72.6 million in 2024 revenue, so each additional procedure can move results, but the real value is tied to outcomes, site-of-care economics, and coverage rules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital And Consumable Mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChartis combines a capital console with a balloon catheter, while StratX is a cloud-based analysis platform. That gives Pulmonx Corporation a price stack with upfront equipment, disposable use, and software-style recurring fees, so one sale can trigger repeat revenue. \u003c\/p\u003e\n\u003cp\u003eThis mix matters because the console is a durable asset, the catheter is tied to each procedure, and StratX supports ongoing access and analysis. So the company can price for hardware adoption and still build subscription-like cash flow over time. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital: console\u003c\/li\u003e\n\u003cli\u003eDisposable: balloon catheter\u003c\/li\u003e\n\u003cli\u003eRecurring: cloud analysis\u003c\/li\u003e\n\u003cli\u003eRevenue mix: upfront plus repeat\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement Dependent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePulmonx Corporation’s pricing is reimbursement dependent: for procedure-based medtech, payer coverage and hospital budgets matter more than a simple sticker price. If a therapy lacks clear reimbursement, adoption can stall even when clinical demand exists, so market access drives realized pricing.\u003c\/p\u003e\n\u003cp\u003eThis is especially true in hospitals facing fixed budgets and case-cost scrutiny, where each procedure must fit both payer payment and supply economics. Pulmonx’s value is tied to how fast payers approve and how broadly centers can bill for the intervention.\u003c\/p\u003e\n\u003cp\u003eIn short, reimbursement sets the ceiling for price and the pace of adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage drives adoption faster than list price.\u003c\/li\u003e\n\u003cli\u003eHospital budgets shape pricing power.\u003c\/li\u003e\n\u003cli\u003eMarket access can matter more than demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePulmonx Pricing: Negotiated, Not Posted\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePulmonx Corporation’s price is negotiated, not posted, because Zephyr Valve and Chartis are sold to hospitals and procedure centers. That keeps realized pricing tied to reimbursement, training, and site economics, not a public list price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice factor\u003c\/th\u003e\n\u003cth\u003eFact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eHospital\/institutional\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic list price\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$72.6M in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234593186057,"sku":"lung-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lung-marketing-mix.webp?v=1785724333","url":"https:\/\/dcfanalyst.com\/products\/lung-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}